Clinical Trial Update: Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm [Phase 2]

View source ↗

Summary

Clinical trial update indicating the Phase 2 study of adjuvant osimertinib in non-small cell lung cancer with uncommon EGFR mutations is currently active but no…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• TAGRISSO (osimertinib)

Snippet

Sponsor: AstraZeneca | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING